|
Return
to main press room
page
FOR IMMEDIATE RELEASE
Therion Appoints Former Wyeth-Lederle
Vaccines President,
Ronald J. Saldarini, Ph.D., to Board of
Directors
Cambridge, MA, December 6, 1999 - Therion
Biologics Corporation today announced the
appointment of Ronald J. Saldarini, Ph.D., to its
Board of Directors. Dr. Saldarini, retired
President, Wyeth-Lederle Vaccines and Pediatrics,
brings to Therion over 30 years of experience in
the pharmaceutical industry.
"We are fortunate to have attracted such a talented
industry executive to our Board of Directors," said
Dennis L. Panicali, Ph.D., President and Chief
Executive Officer of Therion. "We have utilized our
proprietary pox virus vector technology to develop
and advance seven therapeutic cancer vaccine
candidates and one AIDS vaccine candidate into
multiple Phase I and II clinical studies. Ron's
industry insight and his expertise in
pharmaceutical and vaccine research, development
and manufacturing will serve as a valuable resource
as we advance our products into late-stage clinical
trials."
Dr. Saldarini served as President of Wyeth-Lederle
Vaccines and Pediatrics, a business unit of
American Home Products Corporation (AHP), from 1995
until his retirement in 1999. At AHP, Dr. Saldarini
was responsible for management of the Wyeth-Ayerst
Laboratories Vaccines, U. S. Infant Nutritionals
and Pediatric Pharmaceuticals business units. From
1969 until 1994, he held a variety of positions at
American Cyanamid Company including President,
Lederle-Praxis Biologicals Division. At American
Cyanamid, Dr. Saldarini supervised the business
operations and management of research and
development activities for the Company's
Lederle-Praxis division in the U.S. In addition, he
managed the strategic direction of American
Cyanamid's global vaccine and biological products
business.
Dr. Saldarini has served as a member of several
national committees, including the National Vaccine
Advisory Committee and the National Advisory
Commission on Childhood Vaccines. He is currently a
member of the Boards of Trustees of the National
Foundation of Infectious Diseases and the
Infectious Disease Institute of New Jersey, the
Board of Directors of the Institute for the
Advanced Studies of Immunology and Aging, the
Policy Board of the Albert B. Sabin Vaccine
Foundation, and numerous other scientific councils
and professional societies. Dr. Saldarini received
his Ph.D. in physiology and biochemistry from the
University of Kansas and completed an NIH
postdoctoral fellowship at the Brain Research
Institute of the UCLA School of Medicine.
Therion Biologics Corporation is engaged in the
development of therapeutic vaccines for cancer and
preventive vaccines for AIDS. Currently, Therion
has seven products in Phase I and Phase II clinical
development for the treatment of major cancers,
including prostate, colorectal and breast cancer
and melanoma. The Company also has a major
corporate alliance with Pasteur Mérieux
Connaught for the development of therapeutic
colorectal cancer and melanoma vaccines. Therion is
headquartered in Cambridge, Massachusetts.
|
Contacts:
Dennis L. Panicali, Ph.D.
President and CEO
Therion Biologics Corporation
(617) 876-7779
|
Heidi Sprang or
Sharon Karlsberg
Feinstein Kean Healthcare Inc
(617) 577-8110
http://www.fkhealth.com
|
###
Back to
the top
|
|
